Research output per year
Research output per year
Personal profile
Research Interests
Walid has research experience in conventional formulation development and nanoparticle-based drug delivery systems as well as extensive analytical chemistry experience. His current research focuses on the discovery and development of advanced vaccine formulations for novel synthetic pattern recognition receptor (CLR and TLR) ligands (adjuvants) to promote long-term immunity to serious infectious diseases such as tuberculosis, influenza (flu), and COVID-19 as well as developing next-generation immunomodulators to fight cancer.
Education/Academic qualification
Master, Pharmaceutical Chemistry, Cairo University
Bachelor, Pharmaceutical Sciences, Cairo University
Doctorate, Analytical Chemistry, Georgia State University
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being -
SDG 16 Peace, Justice and Strong Institutions
Fingerprint
Dive into the research topics where Walid Abdelwahab is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
- 21 Article
-
Encapsulation of the lipidated TLR7/8 agonist INI-4001 into ionic liposomes impacts H7 influenza antigen-specific immune responses
Mehradnia, F., Amin, H., Ferrini, M. E., Partlow, H., Borgogna, T., Dachavaram, S. S., T. Ryter, K., Bazin, H. G., Evans, J. T., Burkhart, D. J., DeBuysscher, B. & Abdelwahab, W. M., Feb 2026, In: Drug Delivery and Translational Research. 16, 2, p. 661-674 14 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Mincle receptor agonist UM-1098 and TLR4 agonist INI-2002 combination adjuvant enhances Th1 responses and provides protection against Mycobacterium tuberculosis challenge in mice
Rungelrath, V., Jones, G., Ahmed, M., Taneja, V., Riffey, A., Abdelwahab, W. M., Das, S., Khader, S. A. & Evans, J. T., Oct 2025, In: Vaccine: X. 26, 100699.Research output: Contribution to journal › Article › peer-review
Open Access -
The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine
Crawford, M. W., Abdelwahab, W. M., Siram, K., Parkins, C. J., Harrison, H. F., Stone, E. T., Osman, S. R., Schweitzer, D., Burkhart, D. J., Pinto, A. K., Brien, J. D., Smith, J. L. & Hirsch, A. J., Dec 2025, In: npj Vaccines. 10, 1, 156.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Co-Delivery of a Novel Lipidated TLR7/8 Agonist and Hemagglutinin-Based Influenza Antigen Using Silica Nanoparticles Promotes Enhanced Immune Responses
Abdelwahab, W. M., Auclair, S., Borgogna, T., Siram, K., Riffey, A., Bazin, H. G., Cottam, H. B., Hayashi, T., Evans, J. T. & Burkhart, D. J., Jan 2024, In: Pharmaceutics. 16, 1, 107.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Co-Delivery of Novel Synthetic TLR4 and TLR7/8 Ligands Adsorbed to Aluminum Salts Promotes Th1-Mediated Immunity against Poorly Immunogenic SARS-CoV-2 RBD
Siram, K., Lathrop, S. K., Abdelwahab, W. M., Tee, R., Davison, C. J., Partlow, H. A., Evans, J. T. & Burkhart, D. J., Jan 2024, In: Vaccines. 12, 1, 21.Research output: Contribution to journal › Article › peer-review
Open Access10 Scopus citations